Amifostine does not inhibit the toxic effects of anthracycline derivates or mitoxantrone on MDR tumor cell lines

Leukemia and Lymphoma

Volumn 42, Issue 4, 2001, Pages 721-729

  Michieli, M ^a   Michelutti, A ^a   Damiani, D ^a   Ermacora, A ^a   Masolini, P ^a   Stocchi, R ^a   Russo, D ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Amifostine; Anthracyclines; LRP; MDR; MRP; Multi drug resistance; PGP; WR 1065

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ALKYLATING AGENT; AMIFOSTINE; ANTHRACYCLINE; ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE; CISPLATIN; CYCLOSPORIN; CYTOTOXIC AGENT; DAUNORUBICIN; DOXORUBICIN; DRUG METABOLITE; ETOPOSIDE; GLYCOPROTEIN P; IDARUBICIN; LUNG RESISTANCE PROTEIN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PENICILLIN G; PLATINUM DERIVATIVE; STREPTOMYCIN; TAXANE DERIVATIVE; VALSPODAR; VERAPAMIL; VINCRISTINE;

ACUTE LEUKEMIA; ARTICLE; CELL LINE; CELL PROTECTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; HUMAN; HUMAN CELL; IN VIVO STUDY; INCUBATION TIME; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034861755     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190109099334     Document Type: Article

References (29)

1. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells
2. Screening for multidrug resistance in leukemia: Cell reactivity to MRK16 correlates with anthracyclines retention and sensitivity of leukemic cells
3. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy
4. P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias
5. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukemias: Biological and clinical implications
6. Restoring uptake and retention of daunorubicin and idarubicin in P170-related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC 833
7. Phase I/II trial of cyclosporine as a chemotherapy resistance modifier in acute leukemia
8. Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia
9. Phase I/II clinical and pharamcokinetic evaluation of liposomal daunorubicin
10. Liposome encapsulated Daunorubicin for PGP-related multidrug resistance
11. The role of WR-2721 in radiotherapy and or chemotherapy
12. Amifostine: The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies
13. WR-1065, the active metabolite of amifostine (ethiol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells
14. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained
15. Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro
16. P170-dependent multidrug resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporin A derivatives
17. Evaluation of the clinical relavance of the anionic glutathione-s-transferase (GSTπ) and multidrug resistance (mdr-1) gene coexpression in leukemias and lymphomas
18. A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline derivatives
19. Drug transport variant without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin
20. Resistance-associated factors in human small-cell lung carcinoma GLC4 sublines with increasing adriamycin resistance
21. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine
22. Selective inhibition of the nephrotoxicity of cis-dichlorodiammineplatinum (II) by WR-2721 without altering its antitumour properties
23. Amifostine protects primitive human hematopoietic progenitors against cytotoxicity from diverse antineoplastics
24. The preclinical basis for broad spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine
25. Expression of the multidrug resistance-associated protein (MRP) in acute leukemia
26. Multidrug resistant cells with high proliferative capacity determine response to therapy in acute myeloid leukemia
27. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
28. Glutathione conjugate transport in intracellular vesicles in the doxorubicin resistant human lung carcinoma cell line GLC4-Adr is MRP mediated
29. ATP- and glutathione-dependent transport of chmotherapeutic drugs by the multidrug resistance protein MRP1